PRMT5 protein inhibitors - Pipeline Insight, 2024

PRMT5 protein inhibitors - Pipeline Insight, 2024

DelveInsight’s, “PRMT5 protein inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 9+ companies and 10+ pipeline drugs in PRMT5 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

PRMT5 protein inhibitors Understanding

PRMT5 protein inhibitors: Overview

Protein arginine methyltransferase 5 (PRMT5) is a critical regulatory protein linked to genome organization, cell cycle regulation, and stem cell differentiation1. It forms an active complex with MEP50 and transfers methyl groups from S-adenosylmethoinine (SAM) to histone proteins, transcription factors, and other regulatory proteins. These methylations form mono and symmetrically di-methylated arginine residues. Dysregulation of PRMT5 activity is associated with many cancers including lymphomas, lung cancer, and breast cancer. Additionally, PRMT5 is linked to kidney disease, heart disease, and neurological disorders including Huntington’s and Alzheimer’s. Recent scientific breakthroughs have caused PRMT5 to emerge as a promising new drug target. New findings in both the specific inhibition of PRMT5 and in metabolic pathways linked to its activity have brought new attention to this important protein.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence PRMT5 protein inhibitors R&D. The therapies under development are focused on novel approaches for PRMT5 protein inhibitors.

PRMT5 protein inhibitors Emerging Drugs Chapters

This segment of the PRMT5 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

PRMT5 protein inhibitors Emerging Drugs

• PRT811: Prelude Therapeutics

PRT811, Prelude’s second clinical product candidate, is an oral PRMT5 inhibitor under development for patients with PRMT5-dependent cancers, including central nervous system (CNS) tumors such as glioblastoma multiforme (GBM) and primary CNS lymphoma. PRT811 is designed to have high potency and selectivity and optimized brain exposure. PRT811 is being studied in a Phase 1 clinical trial in solid tumors, including GBM and primary central nervous system lymphomas (PCNSL).

• Pemrametostat: GlaxoSmithKline

Pemrametostat (formerly GSK 3326595) is an oral inhibitor of protein arginine methyltransferase 5 (PRMT 5), being developed by GlaxoSmithKline. Currently, it is in Phase II stage of clinical trial evaluation to treat Non-Hodgkin's lymphoma and solid tumors.

Further product details are provided in the report……..

PRMT5 protein inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different PRMT5 protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on PRMT5 protein inhibitors

There are approx. 9+ key companies which are developing the PRMT5 protein inhibitors. The companies which have their PRMT5 protein inhibitors drug candidates in the most advanced stage, i.e. Phase II include, GlaxoSmithKline.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

PRMT5 protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

PRMT5 protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses PRMT5 protein inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging PRMT5 protein inhibitors drugs.

PRMT5 protein inhibitors Report Insights

• PRMT5 protein inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

PRMT5 protein inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing PRMT5 protein inhibitors drugs?
• How many PRMT5 protein inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of PRMT5 protein inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the PRMT5 protein inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for PRMT5 protein inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Prelude Therapeutics
• GlaxoSmithKline
• Pfizer
• Amgen
• Mirati Therapeutics
• Jubilant Biosys
• Agios Pharmaceuticals
• Tango Therapeutics
• Lead Pharma
• Argonaut Therapeutics

Key Products

• PRT811
• Pemrametostat
• AMG 193
• PRT 543
• PF 06939999
• MRTX 1719
• MRTX 4646
• JPRMT 5i
• AT101
• TNG908
• JBI 778